Business
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
WESTMINSTER, Colo., April 09, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada.
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"WESTMINSTER, Colo., April 09, 2026--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada.","length":487,"tagName":"p"},{"type":"text","content":"TriSalus will showcase new clinical and preclinical data highlighting the capabilities of its Pressure Enabled Drug Delivery™ (PEDD™) platform to enhance therapeutic delivery across multiple disease states.","length":206,"tagName":"p"},{"type":"text","content":"Featured presentations include:","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"April 13, 2026 | 12:10 PM ET David Jaroch, PhD (TriSalus Life Sciences) Poster Presentation: Pressure Enabled Drug Delivery During Delivery of Embolic Spheres Enhances Hepatic Tumor Penetration in an Oncopig Model","length":216,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"April 13, 2026 | 3:18 PM ET Adam Robinson, MS (Tulane University) and Richard Marshall, MD (Tulane University and TriSalus Life Sciences) Scientific Session Presentation: Embolization of Neuroendocrine Tumor Metastases to the Liver: A Single-Center Experience Before and After the Introduction of Pressure Enabled Drug Delivery","length":330,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"April 14, 2026 | 3:36 PM ET Francis Kang, MD (Rutgers Robert Wood Johnson Medical School) Scientific Session Presentation: Novel Approaches to Uterine Artery Embolization: A Clinical Assessment of Safety and Efficacy Using a Pressure Enabled Drug Delivery Device","length":265,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":811,"olType":false},{"type":"text","content":"Additional abstracts and presentation materials are available at:https://trisaluslifesci.com/publications-presentations/","length":121,"tagName":"p"},{"type":"text","content":""These presentations continue to expand the growing body of evidence supporting PEDD as a differentiated approach to improving therapeutic delivery," said Mary Szela...